Most scientists 'can't replicate studies by their peers'Well, that actually IS fraud. It is fraud which is systemically induced and supported. And that means that the scientists are complicit and the data is fundamentally useless. A giant taxpayer rip-off.
Science is facing a "reproducibility crisis" where more than two-thirds of researchers have tried and failed to reproduce another scientist's experiments, research suggests.
This is frustrating clinicians and drug developers who want solid foundations of pre-clinical research to build upon.
From his lab at the University of Virginia's Centre for Open Science, immunologist Dr Tim Errington runs The Reproducibility Project, which attempted to repeat the findings reported in five landmark cancer studies.
"The idea here is to take a bunch of experiments and to try and do the exact same thing to see if we can get the same results."
You could be forgiven for thinking that should be easy. Experiments are supposed to be replicable.
The authors should have done it themselves before publication, and all you have to do is read the methods section in the paper and follow the instructions.
Sadly nothing, it seems, could be further from the truth.
After meticulous research involving painstaking attention to detail over several years (the project was launched in 2011), the team was able to confirm only two of the original studies' findings.
According to a survey published in the journal Nature last summer, more than 70% of researchers have tried and failed to reproduce another scientist's experiments.
Marcus Munafo is one of them. Now professor of biological psychology at Bristol University, he almost gave up on a career in science when, as a PhD student, he failed to reproduce a textbook study on anxiety.
"I had a crisis of confidence. I thought maybe it's me, maybe I didn't run my study well, maybe I'm not cut out to be a scientist."
The problem, it turned out, was not with Marcus Munafo's science, but with the way the scientific literature had been "tidied up" to present a much clearer, more robust outcome.
"What we see in the published literature is a highly curated version of what's actually happened," he says.
"The trouble is that gives you a rose-tinted view of the evidence because the results that get published tend to be the most interesting, the most exciting, novel, eye-catching, unexpected results.
"What I think of as high-risk, high-return results."
The reproducibility difficulties are not about fraud, according to Dame Ottoline Leyser, director of the Sainsbury Laboratory at the University of Cambridge.
That would be relatively easy to stamp out. Instead, she says: "It's about a culture that promotes impact over substance, flashy findings over the dull, confirmatory work that most of science is about."
She says it's about the funding bodies that want to secure the biggest bang for their bucks, the peer review journals that vie to publish the most exciting breakthroughs, the institutes and universities that measure success in grants won and papers published and the ambition of the researchers themselves.
"Everyone has to take a share of the blame," she argues. "The way the system is set up encourages less than optimal outcomes."
"Replication is something scientists should be thinking about before they write the paper," says Ritu Dhand, the editorial director at Nature.Today's "science" is on the rocks. You can bet on two things: Whatever is published in science journals is likely to be neither complete nor valid; the last line in the study goes something like this: "more study is needed".
But we need to be bolder, according to the Edinburgh neuroscientist Prof Malcolm Macleod.
"The issue of replication goes to the heart of the scientific process."
"Without efforts to reproduce the findings of others, we don't know if the facts out there actually represent what's happening in biology or not."
Without knowing whether the published scientific literature is built on solid foundations or sand, he argues, we're wasting both time and money.
"It could be that we would be much further forward in terms of developing new cures and treatments. It's a regrettable situation, but I'm afraid that's the situation we find ourselves in."